Navelbine and Herceptin combination as first line therapy for HER 2- overexpressing metastatic breast cancer is a highly active and safe regimen. Final results of multinational trial
- Kellokumpu-Lehtinen, P. (Speaker)
Activity: Talk or presentation › Conference presentation